Sandbox g53: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) (Created page with "{{PBI|HHV-7}} :* Most patients with infection with HHV-7 will be asymptomatic. It is unknown whether treatment in asymptomatic patients will lead to a reduction in subsequent...") |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
:* For HIV-positive patients, antiretroviral therapy may be advisable. (sanford) | :* For HIV-positive patients, antiretroviral therapy may be advisable. (sanford) | ||
:* There are no defined circumstances that warrant specific antiviral therapy for HHV-7. (10578120) | :* There are no defined circumstances that warrant specific antiviral therapy for HHV-7. (10578120) | ||
:* The most active antiviral compounds against HHV-7 are [[Cidofovir]] and [[Foscarnet]]. (11747000) | :* The most active antiviral compounds against HHV-7 are [[Cidofovir]] and [[Foscarnet]]. (11747000) | ||
Latest revision as of 15:53, 13 July 2015
- HHV-7
Return to Top
- Most patients with infection with HHV-7 will be asymptomatic. It is unknown whether treatment in asymptomatic patients will lead to a reduction in subsequent infection. (15504215)
- Immunocompetent hosts with uncomplicated skin manifestations associated with HHV-7, particularly roseola infantum and pityriasis rosea, need only symptomatic management. (22819486)
- For HIV-positive patients, antiretroviral therapy may be advisable. (sanford)
- There are no defined circumstances that warrant specific antiviral therapy for HHV-7. (10578120)
- The most active antiviral compounds against HHV-7 are Cidofovir and Foscarnet. (11747000)